Teva Pharmaceutical Introduces Nicardipine Hydrochloride Injection
More News related to TEVA
- Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
- Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
- Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)
- Teva Pharmaceutical (TEVA) and Active Biotech Complete Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
- Teva Pharma (TEVA) and Active Biotech Complete Patient Enrollment for Second Pivotal Phase III Trial of Laquinimod
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced the introduction of Nicardipine Hydrochloride Injection, 2.5 mg/mL, which is AP-rated to EKR Therapeutics' hypertension treatment Cardene(R) I.V. Teva's product is the first alternative to the brand product, which had annual sales of approximately $181 million in the United States for the twelve months ended June 30, 2008, according to IMS sales data.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company.[SM]
Related Categories
Corporate NewsStocks Mentioned
-0.49Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
